Eli Lilly’s Elanco unit blossoming at just the right time
An investment firm projects that the Elanco animal-health business will generate sales of nearly $2 billion by 2012 and surpass $3 billion by 2018.
Pharmaceutical
Articles
Despite sales spike, Effient has middling prospects
Remember Effient? The blood thinner that was once Eli Lilly and Co.’s greatest post-Zyprexa hope and then, after a slow launch, was dismissed as an abject failure? Well, it’s turning out to defy both predictions.
UPDATE: Medco acquisition could lead to local consolidation
It’s not yet clear how Express Scripts Inc.’s $29.1 billion acquisition of rival Medco Health Solutions will affect the companies’ central Indiana operations—or their 800-plus employees at two facilities here.
Express Scripts to buy Medco for $29.1B in cash, stock
Express Scripts Inc. agreed to buy Medco Health Solutions Inc. for $29.1 billion to become the largest pharmacy-benefits manager in the United States. Both have central Indiana operations.
Lilly profit falls, but forecast rises after second quarter
Second-quarter profit fell at Eli Lilly and Co., but the Indianapolis drugmaker beat the estimates of Wall Street analysts by a penny per share and raised its full-year profit forecast by as much as 10 cents per share.
Lilly: Alzheimer’s patients on failed drug didn’t improve
Eli Lilly and Co. said patients with Alzheimer’s disease whose conditions worsened upon taking the experimental drug semagacestat didn’t improve after dosing was halted.
FDA says potential diabetes drug may cause cancer
Dapagliflozin would be the first in a new class of diabetes treatments called SGLT2-inhibitors that work by letting patients excrete excess blood sugar in their urine. Indianapolis-based Eli Lilly and Co. is among several companies pursuing similar drugs.
Lechleiter: German drug pricing creates ‘uncertainty’ for Lilly
Eli Lilly & Co. CEO John C. Lechleiter said Germany’s overhaul of drug pricing lacked transparency and the new policy creates “uncertainty” for the company’s business planning.
Lilly’s Cialis finally overtakes Viagra
Why do drugmakers still pursue so many me-too drugs? Because, if marketed well, they can be extremely lucrative. Just ask Eli Lilly and Co. about its drug Cialis.
R&D spending soars above value of new drugs
To understand the depths of the pharmaceutical industry’s recent struggles, consider this: The industry has been spending $57 billion more per year on research and development than the value of the products it has been launching. That’s a problem.
Lilly asks judge to reject U.K. Zyprexa case
Eli Lilly and Co., the Indianapolis-based drugmaker whose best-selling schizophrenia medicine Zyprexa survived a patent challenge in Britain two years ago, has asked a United Kingdom judge to reject a parallel lawsuit by a generic drug company.
Timing good for 2-in-1 biotech drugs
Eli Lilly and Co.’s foray into combination drugs is well-timed because the company could take advantage of some the world’s most successful biotech medicines, which are about to see their patents expire.
Lilly plans 10 drugs in final-stage trials by year’s end
Lilly has 33 drugs in the second and third stages of clinical trials, including medicines for cancer, diabetes and Alzheimer’s disease, up from seven in 2005, the Indianapolis-based company said Thursday.
Quarterly lobbying bill adds up to $2.5M for Lilly
Indianapolis-based Eli Lilly and Co. raised its spending 8 percent from the $2.3 million that it spent in the first quarter of last year. The drugmaker also spent 70 percent more than the $1.5 million recorded in the final quarter of 2010, according to lobbying reports filed with the House of Representatives.
Lilly plans more investment in two-in-one drugs
Indianapolis-based drugmaker Eli Lilly on Tuesday will announce a multimillion-dollar investment to develop drugs that act like two medicines in one. Lilly plans to add more scientists to back the effort.
Zyprexa appeal rejected by Supreme Court
The U.S. Supreme Court has refused to revive a bid to press a $6.8 billion class-action suit against Eli Lilly and Co. over the marketing of Zyprexa, the company’s schizophrenia treatment.
Lilly, partner find no Bydureon effect on heart rhythm
Eli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. said an analysis of a 148-patient trial found no evidence that their experimental Bydureon diabetes drug causes prolonged heart rhythms.
Lilly diabetes pill recommended for EU approval
Eli Lilly and Co. and Boehringer Ingelheim GmbH’s Trajenta medicine for Type 2 diabetes has been recommended for approval in Europe, putting the drug on track to enter the region’s market this year.
EU approves Lilly’s weekly diabetes drug Bydureon
European Union regulators have approved the first once-per-week diabetes medication, the companies that developed the drug said Tuesday.
Analyst: Lilly drug poised for continued growth
Eli Lilly and Co.'s lung cancer treatment Alimta is poised for continued growth based on recently released study data, according to a new Credit Suisse analyst report.